Loading market dashboard
Sanofi
SNYHealthcareNASDAQFR
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin's AI Scientist. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The co.
Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries.
SAN FRANCISCO--(BUSINESS WIRE)-- #SnowflakeSummit--SNOWFLAKE SUMMIT 26 – Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced at Snowflake Summit 26 that Sanofi, one of the world's leading biopharmaceutical companies, has established a new blueprint for AI-powered biopharma with its launch of "Concierge for Field," a new AI agent built with Snowflake Cortex AI that prepares Sanofi's global sales representatives for every physician or provider visit. In a single conversation, a rep can ask for a pre-.
Sanofi secures FDA priority review for venglustat in GD3, setting up a November decision on a potential first U.S. therapy for neurological symptoms.
Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder.
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease.
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
I highlight five dividend stocks—HTO, ES, SNY, NLY, and AMCR—trading below fair value, each with strong balance sheets and good potential growth prospects. Each stock is projected to deliver double-digit average annual total returns (11.6%–20%) through 2030, with yields averaging nearly 7%. Scenario modeling incorporates expected EPS growth, dividend growth, and target P/E multiples, supporting robust total return forecasts even in recessionary or inflationary environments.
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Sanofi (SNY) is rated a Strong BUY, with a robust pipeline, strong FCF, and a compelling turnaround under new leadership. SNY offers a 5.5%+ dividend yield, undervalued multiples, and projected 16–20% annualized total returns over the next five years. Recent product launches drove 14% of Q1 revenue, with 80 pipeline products and 23 in mid-to-late stage development supporting future growth.
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Sanofi has asked the U.S. Food and Drug Administration to pull its diabetes drug out of the regulator's new fast-track review program, STAT News reported on Wednesday.
The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation, today announced Sanofi as one of its inaugural industry sponsors.
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on April 29, 2026, under the chairmanship of Frédéric Oudéa.
Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing performance, continue to make good on their commitments to return more capital to shareholders.
Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million fixed-rate notes, due May 2029, bearing interest at an annual rate of 3.000% €650 million fixed-rate notes, due May 2033, bearing interest at an annual rate of 3.375% €650 million fixed-rate notes, due May 2037, bearing interest at an annual rate of 3.750% The notes are being issued under Sanofi's Euro Medium Term Note programme. Sanofi intends to use the net proceeds of the offering for general corporate purposes.
Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.
Sanofi beats Q1 estimates as Dupixent and new drugs fuel double-digit growth, with strong sales and earnings gains supporting its 2026 outlook.
Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for its blockbuster asthma and eczema drug Dupixent.
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3 Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1D Paris, April 22, 2026. The US Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D.
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target action date for its review of the biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) in combination with approved standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all currently approved US indications of Sarclisa intravenous (IV) formulation.
On April 23, Sanofi will report its results for the first quarter of 2026. As a reminder, its revenue grew 23.1% year-over-year to $13.53 billion in Q4 last year. Meanwhile, Sanofi's non-GAAP P/E ratio [FWD] is 9.66x, which, in my view, clearly indicates that it is trading at a discount.
Assetmark Inc. boosted its position in Sanofi (NASDAQ: SNY) by 24.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 443,668 shares of the company's stock after purchasing an additional 86,496 shares during the period. Assetmark Inc.'s holdings in
Sanofi (NASDAQ: SNY - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect Sanofi to post earnings of $0.9330 per share and revenue of $10.8086 billion for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the
Top insights from the latest market news from Tuesday, April 14, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi posts strong mid-stage results for lunsekimig in asthma and CRSwNP but a setback in atopic dermatitis clouds the broader clinical picture.
Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig's potential as a respiratory treatment The exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis In all studies, lunsekimig was well tolerated Paris, April 7, 2026. Phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo.
Aberdeen Group plc lifted its stake in shares of Sanofi (NASDAQ: SNY) by 22.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 467,241 shares of the company's stock after acquiring an additional 86,314 shares during the quarter. Aberdeen Group plc's
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Euro Pacific Asset Management LLC acquired a new stake in shares of Sanofi (NASDAQ: SNY) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 43,688 shares of the company's stock, valued at approximately $2,111,000. Other large investors also recently bought
Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg.
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the approval of a subcutaneous version of its blood cancer drug administered through an on-body injector.
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results (sanofi.com) Prepared each quarter, this document is intented to support financial modelling of the quarterly results.
Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm's experimental treatment for several autoimmune diseases.
French drugmaker Sanofi launched an innovation and operation centre in the southwestern Chinese city of Chengdu on Thursday, the company said in a statement released on its Chinese social media account on Friday.
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.
After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing.
GAITHERSBURG, Md.--(BUSINESS WIRE)--Mirecule expands strategic collaboration with Sanofi on advancement of best-in-class ARC treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
Sanofi's venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder.
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging on medications for low-income and uninsured patients.
From oil, beauty, and therapeutic resource stocks, @ElliottWaveTrader's Tammy Marshall turns to three companies she sees as unsung market opportunities. The Fibonacci Princess offers insight and example options trades for Permian Resources (PR), e.l.f. Beauty (ELF), and Sanofi (SNY). Rick Ducat adds to Tammy's analysis by giving investors a glimpse at key support and resistance levels.
Sanofi has increased its dividend for 31 consecutive years. That's a fantastic track record. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That's a compound annual growth rate of 2.6%. Sanofi has a great financial position. The long-term debt/equity ratio is 0.2, while the interest coverage ratio is 11.
Callodine Capital Management LP grew its stake in Sanofi (NASDAQ: SNY) by 35.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 698,046 shares of the company's stock after acquiring an additional 182,837 shares during the period. Sanofi accounts for
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own semaglutide-based injector pens in its home market.
Sanofi (NASDAQ: SNY - Get Free Report) shares hit a new 52-week low during mid-day trading on Friday. The company traded as low as $44.01 and last traded at $44.01, with a volume of 93153 shares. The stock had previously closed at $45.00. Analysts Set New Price Targets SNY has been the topic of several
